Hymecromone

Phase 2Small molecule

SStanford University

Hymecromone is one of 108 small molecule programs targeting Interstitial Lung Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

107

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial Lung DiseaseActive, not recruiting

COVID-19Active, not recruiting

Sclerosing CholangitisActive, not recruiting

Interstitial Lung DiseasePhase 2

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Sclerosing CholangitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Hymecromone

SStanford University

Phase 2

1 5

Activella

Eli Lilly

Preclinical

—6

Calciferol

Alnylam Pharmaceuticals

Rayaldee

1 8

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 10

Calcium

Eli Lilly

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Sclerosing Cholangitis

NCT05295680

Phase 2Recruiting

Interstitial Lung Disease

NCT06325696

Clinical

Trials by Indication[1]

Interstitial Lung Disease2 trials

Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).

Completed·SStanford University·Phase 2·NCT05128929·17 enrolled

Phase IIa Investigation of H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

Recruiting·NNational Institute of Environmental Health Sciences (NIEHS)·Phase 2·NCT06325696·37 enrolled

Oral1 trial

A Study of Oral Hymecromone and Hyaluronan Synthesis

Completed·PPaul Bollyky·Phase 1·NCT02780752·12 enrolled

Sclerosing Cholangitis1 trial

Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.

Recruiting·AAparna Goel·Phase 2·NCT05295680·24 enrolled

COVID-191 trial

A Safety and Efficacy Study of Hymecromone Tablets for the Treatment of Patients With COVID-19.

Unknown status·SShanghai Zhongshan Hospital·N/A·NCT05386420·304 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Hymecromone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hymecromone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hymecromone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SStanford University

Hymecromone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Interstitial Lung Disease2 trials

Oral1 trial

Sclerosing Cholangitis1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News